S.301 - Physician Payments Sunshine Act of 2009 Sponsor: Charles Grassley / 111th Congress

Title
111th Congress - A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP. hidemore...
Summary
A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP. (by CRS)
Status
The bill has been introduced.

Customize

Customize the interests supporting and opposing this bill

To remove an interest, click the Remove button next to its name below this box.

To add an interest, choose one from this list:

To add an interest, click Support or Oppose.

You can share your customized pages with other people by sending them the URL for pages about this bill. Other MAPLight.org users will not see your customizations unless they use the URL you send them. To save your customizations for your next visit, create a free New Account, then Sign In.

Done

Interests who did want this bill to become law included these interests and specific groups:

Interests who did not want this bill to become law included these interests and specific groups:

Contribution data provided by the Center for Responsive Politics (OpenSecrets.org)

Comments RSS feed

Demand honest health care at the lowest cost possible by Karen Chung, Apr 30, 2009 (5:50pm)

S. 301 (111th) is an important bill that would shed light upon the relationship between drug manufacturers and physicians. Under the Physician Payments Sunshine Act, physicians who receive $100 or more from pharmaceutical companies and device manufacturers would have to disclose all gifts to the public. Supporters of the bill believe that by publicizing financial relationships, physicians would be dedicated to providing accurate and honest care at the lowest cost. On the other hand, a physician receiving gifts from a pharmaceutical company might opt to prescribe expensive brand name medication manufactured by the company when a cheaper generic option exists.

S. 301 is stricter than the bill that was introduced last session (S. 2029); therefore, it has failed to regain the widespread support it once received from industry groups and organizations such as the American Medical Association.

Reply to this comment
Reply to this comment close
[ Tags ]
[ Tags ] close
[ Spam ]
[ Spam ] close